suramin has been researched along with pci 32765 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adasme, MF; Haupt, VJ; Heinrich, JC; Herman, J; Jennings, GS; Louat, T; Moreau, Y; Parisi, D; Salentin, S; Schroeder, M; Sprangers, B; Van Belle, K | 1 |
1 other study(ies) available for suramin and pci 32765
| Article | Year |
|---|---|
Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Drug Repositioning; Humans; Jurkat Cells; Piperidines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Suramin; Vascular Endothelial Growth Factor Receptor-2 | 2020 |